BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE